.Attributes Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a median follow-up of 11 months, patients with metastatic gastrointestinal lumps that received biomarker-matched therapies based upon distributing tumor DNA profiling revealed a higher professional advantage than those getting incomparable treatment.